Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension
Article first published online: 5 APR 2011
© 2011 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 13, Issue 4, pages 224–237, April 2011
How to Cite
Hsueh, W. A. and Wyne, K. (2011), Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension. The Journal of Clinical Hypertension, 13: 224–237. doi: 10.1111/j.1751-7176.2011.00449.x
- Issue published online: 5 APR 2011
- Article first published online: 5 APR 2011
- Manuscript received January 18, 2011; accepted January 30, 2011
Activation of the renin-angiotensin-aldosterone system (RAAS) is the primary etiologic event in the development of hypertension in people with diabetes mellitus. Modulation of the RAAS has been shown to slow the progression and even cause regression of the microvascular and macrovascular complications associated with diabetes mellitus. Early pharmacotherapy with agents that decrease RAAS activation in the adipose tissue have had a dramatic impact on the prevalence of diabetes related complications. Recent data show that preventing the development of “angry fat” can prevent not just hypertension but also type 2 diabetes mellitus and its associated complications. This review updates what is known about angry fat and the role of RAAS inhibition in preventing the metabolic sequelae of local RAAS activation. J Clin Hypertens (Greenwich). 2011;13:224–237. © 2011 Wiley Periodicals, Inc.